Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.

NCT04357613 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT04357613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04357613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.
Lead sponsor
Versailles Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2020
Completion date
December 1, 2021
Enrollment
99 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sars virus